Literature DB >> 3001230

Receptor binding activities of biotinylated derivatives of beta-nerve growth factor.

M B Rosenberg, E Hawrot, X O Breakefield.   

Abstract

beta-nerve growth factor (NGF) was modified by biotinylation via carboxyl group substitution (C-bio-NGF) using biotin hydrazide and the coupling reagent 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide, under reaction conditions that yielded an average of 3 biotin additions per NGF subunit. NGF was also biotinylated through amino group substitution, using N-hydroxysuccinimidyl biotin, to produce derivatives with ratios of one, two, and four biotin moieties per NGF subunit (N-bio-NGF). The various biotinylated NGF derivatives were compared with native NGF for their capacity to compete with 125I-NGF for binding to NGF receptors on rat pheochromocytoma (PC12) cells at 4 degrees C. On the basis of such radioreceptor assays, C-bio-NGF was as effective as native NGF in binding to NGF receptors. C-bio-NGF was also as effective as native NGF in promoting neurite outgrowth from PC12 cells. In contrast, N-bio-NGF containing one biotin per NGF subunit was only 28% as active in binding as native NGF. Increasing the biotin:NGF ratio to 2 to 4 further decreased receptor binding to 13% and 6%, respectively, as compared to native NGF. Once bound to cells, C-bio-NGF had the capacity to mediate the specific binding of 125I-streptavidin to PC12 cells. This binding of streptavidin was prevented by excess native NGF and by antiserum to NGF, but not by RNase A, insulin, cytochrome c, or nonimmune serum. In addition, a variant PC12 line lacking functional NGF receptors was not labeled by 125I-streptavidin after prior incubation with C-bio-NGF.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3001230     DOI: 10.1111/j.1471-4159.1986.tb13015.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  15 in total

1.  Carboxyl-directed pegylation of brain-derived neurotrophic factor markedly reduces systemic clearance with minimal loss of biologic activity.

Authors:  T Sakane; W M Pardridge
Journal:  Pharm Res       Date:  1997-08       Impact factor: 4.200

2.  Detection of the ganglioside N-glycolyl-neuraminyl-lactosyl-ceramide by biotinylated Escherichia coli K99 lectin.

Authors:  A Ouadia; Y Karamanos; R Julien
Journal:  Glycoconj J       Date:  1992-02       Impact factor: 2.916

3.  Preparation, characterization and biological properties of biotinylated derivatives of calmodulin.

Authors:  J W Polli; M L Billingsley
Journal:  Biochem J       Date:  1991-05-01       Impact factor: 3.857

4.  Combined use of carboxyl-directed protein pegylation and vector-mediated blood-brain barrier drug delivery system optimizes brain uptake of brain-derived neurotrophic factor following intravenous administration.

Authors:  W M Pardridge; D Wu; T Sakane
Journal:  Pharm Res       Date:  1998-04       Impact factor: 4.200

5.  The in vitro biological effect of nerve growth factor is inhibited by synthetic peptides.

Authors:  F M Longo; T K Vu; W C Mobley
Journal:  Cell Regul       Date:  1990-01

6.  Biotinylated epidermal growth factor: a useful tool for the histochemical analysis of specific binding sites.

Authors:  K Kayser; G Weisse; H J Gabius; T Hintze
Journal:  Histochem J       Date:  1990-08

7.  Nerve growth factor: structure/function relationships.

Authors:  R A Bradshaw; J Murray-Rust; C F Ibáñez; N Q McDonald; R Lapatto; T L Blundell
Journal:  Protein Sci       Date:  1994-11       Impact factor: 6.725

8.  Modeled structure of the 75-kDa neurotrophin receptor.

Authors:  B S Chapman; I D Kuntz
Journal:  Protein Sci       Date:  1995-09       Impact factor: 6.725

9.  Neuroprotection with noninvasive neurotrophin delivery to the brain.

Authors:  D Wu; W M Pardridge
Journal:  Proc Natl Acad Sci U S A       Date:  1999-01-05       Impact factor: 11.205

10.  Transport of human recombinant brain-derived neurotrophic factor (BDNF) through the rat blood-brain barrier in vivo using vector-mediated peptide drug delivery.

Authors:  W M Pardridge; Y S Kang; J L Buciak
Journal:  Pharm Res       Date:  1994-05       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.